1. Bleehen, NM, Newlands, ES, Lee, SM, Thatcher, LN, Selby, P, Calvert, AH, Rustin, GJS, Brampton, M & Stevens, MFG (1995). Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910–913.
2. Bower, M, Newlands, ES, Bleehen, NM, Brada, M, Begent, RJH, Calvert, H, Colquhoun, I, Lewis, P & Brampton, MH (1997). Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484–488.
3. Brock, CS, Matthews, JC, Brown, G, Newlands, ES & Price, P (1997). In vivo demonstration of 11C-temozolomide uptake by human recurrent high-grade astrocytomas [abstract]. Br J Cancer 75: 1241.
4. Catapano, CV, Broggini, M, Erba, E, Ponti, M, Marianti, L, Citti, L & D’Incalci, M (1987). In vitro and in vivo methazolastone-induced DNA damage and repair in L1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res 47: 4884.
5. Carter, CA, Waud, WR & Plowman, J (1994). Responses of human melanoma, ovarian, and colon tumor xenografts in nude mice to oral temozolomide. Proc Am Assoc Cancer Res 35: 297 (abstract 1769).